SEC Form 4 · accession 0000899243-18-027399
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Horgan
Officer — Chief Medical Officer and EVP
Period of report
Oct 23, 2018
Accepted (ET)
Oct 24, 2018 · 5:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.58 | Oct 23, 2018 | A | 225,000 | A | — | Oct 22, 2028 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F1The Option will vest as to 25% of the shares on October 22, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter